Background: Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP), and greater overall survival (OS) in ABC pts treated with second-line or greater therapy compared with patients who receive conventional Paclitaxel. However, few data are available in the real-life setting, especially for the weekly schedule (wNab-P).
Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study
NATOLI, Clara;
2017-01-01
Abstract
Background: Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP), and greater overall survival (OS) in ABC pts treated with second-line or greater therapy compared with patients who receive conventional Paclitaxel. However, few data are available in the real-life setting, especially for the weekly schedule (wNab-P).File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
